Fig. 4.

The decision curve analysis of the nomogram for 3-year T2DM risk in the training cohort (a) and validation cohort (b). *The blue line represents the net benefit when no participant was considered to exhibit T2DM, while the green line represents the net benefit when all participants were considered to suffer from T2DM. The area among the model curve, “treat none line” (blue line) and “treat all line” (green line), represents the clinical usefulness of the model. The farther the model curve is to the blue and green lines, the better clinical value the nomogram holds. *Using bootstrap resampling (times = 500)